Ricardo Air Quality and Economic Expertise to Help European Commission Reduce Hundreds of Thousands of Premature Deaths From Air Pollution
15.11.2022 03:01:00 EET | Business Wire | Press release
Ricardo, a global strategic environmental and engineering consulting company, has significantly contributed to the European Commission’s revision of the Ambient Air Quality Directive which sets air quality standards for European Union Member States. This Directive underpins the improvement of air quality to reduce the 300,000 premature deaths a year and a significant number of noncommunicable diseases such as asthma, cardiovascular problems and lung cancer, which are still attributed to air pollution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005544/en/
Smog in the city of Milan, Italy (Photo: Business Wire)
Led by Ricardo, a team of air quality experts, including IIASA, Met.No, VITO and Trinomics, carried out an impact assessment into options to revise the legislation. Using scenario modelling to 2050, Ricardo considered what the potential impacts of the new air quality standards could be in relation to public health, the environment and business. Ricardo provided economic expertise to the impact assessment which shows that the benefits of the proposed revision for society far outweigh the costs. The main benefits expected are related to health: including reduced mortality and morbidity, reduced healthcare expenditure, reduced absence from work due to illness and increased productivity at work. Additionally, key benefits for the environment include reduced ozone-related crop yield losses.
A further study, also led by Ricardo, set out suggestions to improve support for local authorities in achieving cleaner air through strengthening air quality monitoring, modelling and plans.
Dr Beth Conlan, Technical Director – Air Quality at Ricardo said: “Ricardo has the longest-established specialist air quality team in the world and, with over 130 experts, one of the largest, and this is reflected in the UK’s position as a world-leader in air quality expertise. As our corporate mission is to create a safe and sustainable world, we are honoured that the European Commission chose to entrust this seminal project to us, which will significantly reduce deaths, improve people’s quality of life and public health in general. Legislation really does push forward change and, in my thirty years of working in this sector, this regulatory revision is likely to be the most far reaching and valuable in terms of improving air quality.”
Ricardo has provided expertise to the European Union (EU) in air quality and climate change since the 1990s, supporting the EU’s drive to lower emissions, through the Green Deal, and air quality directives – the last one of which was enacted in 2008. Ricardo’s air quality team has very well-established capability in air quality assessment and management practice. It was this capability, together with Ricardo’s economic expertise and proven track record in successfully delivering co-beneficial air quality and climate change programmes for the European Commission that led to the Ricardo-managed air quality team working on this project.
In the UK, Ricardo’s air quality expertise is helping the national Government shape strategies that offer routes to delivering national emissions reduction commitments such as the UK’s Clean Air Strategy, the National Air Pollution Control Plan, National Emission Ceilings targets, Environment Act Air Quality targets, and the UK’s net zero strategy, as well as international objectives through the Gothenburg Protocol.
Ends
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005544/en/
Contact information
Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
